Brief: FDA Says Data Insufficient To Conclude Effectiveness Of Replimune's vusolimogene oderparepvec
10/04/2026 17:30
April 10 (Reuters) - FDA: FDA, IN COMPLETE RESPONSE LETTER: DATA WAS INSUFFICIENT TO CONCLUDE SUBSTANTIAL EVIDENCE OF EFFECTIVENESS OF REPLIMUNE'S VUSOLIMOGENE ODERPAREPVEC Further company coverage: REPL.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Replimune
See all newsTrump picks White House adviser Heidi Overton to run FDA, source says (updated)
Brief: Replimune Group, Inc. Files For Mixed Shelf Size Not Disclosed
Brief: Replimune Reports Fiscal First Quarter 2027 Financial Results And Provides Corporate Update
Replimune Q1 net loss narrows as expenses decline
U.S. STOCKS ON THE MOVE-Microsoft, Coastal Financial, Eli Lilly